Medartis Holding AG (SWX:MED)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 953.58M +1.2% |
| Revenue (ttm) | 269.26M +19.8% |
| Net Income | 8.35M +136.7% |
| EPS | 0.67 +139.3% |
| Shares Out | 12.43M |
| PE Ratio | 114.48 |
| Forward PE | 53.64 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,559 |
| Average Volume | 7,176 |
| Open | 74.00 |
| Previous Close | 74.50 |
| Day's Range | 74.00 - 79.70 |
| 52-Week Range | 72.00 - 97.50 |
| Beta | 1.20 |
| RSI | 40.40 |
| Earnings Date | Aug 18, 2026 |
About Medartis Holding AG
Medartis Holding AG, a medical device company, engages in the development, manufacturing, and sales of implant solutions worldwide. The company’s medical devices are used for the treatment of surgical fixation of bone fractures for upper and lower extremities, as well as for the cranio-maxillofacial surgery. It provides products for the hand, wrist, forearm, elbow, shoulder, and foot and ankle, as well as for upper and lower extremities, mandible, midface, orthognathic under the APTUS and MODUS names, as well as CMX services through web portal,... [Read more]
Financial Performance
In 2025, Medartis Holding AG's revenue was 269.26 million, an increase of 19.76% compared to the previous year's 224.83 million. Earnings were 8.35 million, an increase of 136.65%.
Financial StatementsNews
Medartis Holding AG Earnings Call Transcript: H2 2025
2025 saw double-digit organic growth, major acquisitions, and the successful U.S. launch of TOUCH, driving strong performance across all regions. Despite FX and tariff headwinds, margins improved and investments in production and innovation set the stage for 2026 growth.
Medartis Holding AG Earnings Call Transcript: H1 2025
Organic revenue grew 15.3% in H1, with strong EMEA and U.S. performance and successful integration of KeriMedical and NEOORTHO. Raised full-year growth guidance to 14%-16% and maintained high teens EBITDA margin despite tariffs and FX headwinds.
Medartis Holding AG Earnings Call Transcript: H2 2024
Core revenue grew 11.7% to CHF 224.8 million with a 19% EBITDA margin, led by EMEA. 2025 guidance targets 13-15% organic growth and high teens EBITDA margin, with U.S. acceleration and NeoOrtho acquisition set to drive value segment expansion.
Medartis Holding AG Earnings Call Transcript: H1 2024
Achieved 13.1% underlying growth and improved gross margin to 80.3%, with strong U.S. and EMEA performance offset by LATAM and APAC challenges. Revised full-year CER growth guidance to 12%-15% and EBITDA margin to around 15%, while strengthening cash reserves and preparing for future acquisitions.